Everolimus: a new treatment for BHD renal cancer?

Last week the US National Cancer Institute announced a phase II clinical trial to test everolimus, a derivative of rapamycin, in BHD patients with renal cell carcinoma (RCC). The trial is also open to sporadic chromophobe RCC (chRCC) patients. Approximately 85% of BHD-RCC is either chRCC or a chromophobe-oncocytoma hybrid (Pavlovich et al., 2002), but there are no effective treatments available for this RCC subtype. Instead BHD patients undergo partial nephrectomies to excise tumours – while not often impacting greatly on renal function, repetitive surgeries can increase morbidity risks. It is hoped that cancer drugs, such as everolimus, can offer a valid alternative treatment.

Rapamycin, originally an immunosuppressant, is appealing as a cancer treatment due to its anti-proliferative properties – a result of mTOR signalling inhibition. Everolimus, and temsirolimus, were forms of rapamycin derived to have improved hydrophilicity (enabling oral and intravenous use), improved pharmacokinetics, and reduced immunosuppressive and toxic effects. They, like rapamycin, bind FKBP2 to inhibit mTORC1 signalling; a pathway found to be upregulated in a wide range of cancers (Moschetta et al., 2014).

The choice to trial everolimus in BHD patients is based on research that has found increased mTOR signalling in patient RCC and lung cyst samples, BHD cell lines and BHD-mouse kidney tumours (Baba et al., 2008, Hasumi et al., 2009, Nishii et al., 2013). In addition, preclinical studies in mouse models have found that treatment with rapamycin can reduce kidney cyst and tumour growth, and extend life span (Baba et al., 2008 , Chen et al., 2015). There have also been several case reports of BHD patients responding well to everolimus as part of their treatment programme (Nakamura et al., 2013, Benusiglio et al 2014) providing further support for the concept of the trial.

However, the relationship between FLCN and mTOR signalling is not fully understood, and may show tissue-specificity, as other groups have reported reduced mTOR signalling in human cell lines and mice renal cysts (Hartman et al., 2009, Bastola et al., 2013). As such everolimus may not be an effective treatment for all, or even any, BHD pathologies.

Everolimus is already approved as a second line treatment for metastatic RCC, some breast and pancreatic cancers, and subependymal giant cell astrocytoma (SEGA) in TSC patients. There are currently several hundred ongoing clinical trials assessing everolimus in a range of cancers and neurological disorders. In addition it is being trialled in LAM patients to assess impact on pulmonary pathologies (Goldberg et al., 2015) – sirolimus has already been found to halt the progression of lung cyst formation (McCormack et al., 2011) and is an approved treatment for angiomyolipomas in LAM and TSC patients. Topical sirolimus can also be used to treat facial angiofibromas in TSC patients (DeKlotz et al., 2011) but a recent trial assessing its use as a fibrofolliculoma treatment produced inconclusive results (Gijezen et al., 2014) – further discussion of this trial can be found here.

FLCN loss perturbs several signalling pathways, so the optimal treatment for BHD-RCC might be a combination of inhibitors. There are ongoing clinical trials accessing the safety and efficacy of combinatorial or sequential treatment of an mTOR inhibitor and a tyrosine kinase inhibitor (TKI), such as pazopanib or sunitinib, in a range of cancers including metastatic RCC. Further research will also increase our understanding of the biological changes responsible for tumour development in BHD and could help in the development of further targeted treatment options.


  • Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS (2008). Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. Jan 16;100(2):140-54. PMID: 18182616.
  • Bastola P, Stratton Y, Kellner E, Mikhaylova O, Yi Y, Sartor MA, Medvedovic M, Biesiada J, Meller J, Czyzyk-Krzeska MF (2013). Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. PLoS One. Jul 29;8(7):e70030. PMID: 23922894.
  • Benusiglio PR, Giraud S, Deveaux S, Méjean A, Correas JM, Joly D, Timsit MO, Ferlicot S, Verkarre V, Abadie C, Chauveau D, Leroux D, Avril MF, Cordier JF, Richard S, & French National Cancer Institute Inherited Predisposition to Kidney Cancer Network (2014). Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet journal of rare diseases, 9 PMID: 25519458.
  • Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P, Khoo SK, Dykema K, Zhao P, Petillo D, Cao B, Zhang Z, Si S, Schoen SR, Yang XJ, Zhou M, Xiao GQ, Wu G, Nordenskjöld M, Tauc M, Williams BO, Furge KA, Teh BT (2015). Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney Int. Jun 17. PMID: 26083655.
  • DeKlotz CM, Ogram AE, Singh S, Dronavalli S, MacGregor JL (2011). Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol. Sep;147(9):1116-7. PMID: 21931059.
  • Gijezen LM, Vernooij M, Martens H, Oduber CE, Henquet CJ, Starink TM, Prins MH, Menko FH, Nelemans PJ, van Steensel MA (2014). Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial. PLoS One. Jun 9;9(6):e99071. PMID: 24910976.
  • Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP (2015). Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. Jun 25. PMID: 26113676.
  • Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP (2009). The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene. Apr 2;28(13):1594-604. PMID: 19234517.
  • Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM (2009). Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A. Nov 3;106(44):18722-7. PMID: 19850877.
  • McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group (2011). Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. Apr 28;364(17):1595-606. PMID: 21410393.
  • Moschetta M, Reale A, Marasco C, Vacca A, Carratù MR (2014). Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol. Aug;171(16):3801-13. Review. PMID: 24780124.
  • Nakamura M, Yao M, Sano F, Sakata R, Tatenuma T, Makiyama K, Nakaigawa N, Kubota Y (2013). A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents. Hinyokika Kiyo. Aug;59(8):503-6. PMID: 23995526.
  • Nishii T, Tanabe M, Tanaka R, Matsuzawa T, Okudela K, Nozawa A, Nakatani Y, Furuya M (2013). Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt-Hogg-Dubé syndrome. Pathol Int. Jan;63(1):45-55. PMID: 23356225.
  • Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ (2002). Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol. Dec;26(12):1542-52. PMID: 12459621.
Be the first to like.
This entry was posted in BHD Research Blog. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *